Welcome to our dedicated page for Cogent Biosciences news (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.
Cogent Biosciences develops precision therapies for genetically defined diseases, with recurring updates centered on bezuclastinib and KIT-driven disorders including Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST). News commonly covers bezuclastinib clinical data from the SUMMIT and PEAK programs, U.S. FDA New Drug Application activity, medical-meeting presentations and related business updates.
Company announcements also describe preclinical oncology programs such as CGT1263, a KRAS inhibitor candidate, and CGT4255, a brain-penetrant ErbB2/HER2 inhibitor candidate. Financial-result releases and capital updates address cash resources, at-the-market equity activity and Nasdaq inducement equity awards.
Cogent Biosciences has named Cole Pinnow as Chief Commercial Officer, effective May 23, 2024. Pinnow brings 25 years of biopharmaceutical industry experience, including roles at Pfizer where he led a $5B cancer portfolio. At Cogent, Pinnow will oversee the commercial strategy for the anticipated launch of bezuclastinib, aimed at treating systemic mastocytosis (SM) and Gastrointestinal Stromal Tumors (GIST).
His appointment includes inducement equity awards of 525,000 stock options and up to 214,000 performance-based restricted stock units, encouraging long-term company growth. CEO Andrew Robbins highlighted Pinnow's expertise as important for transitioning Cogent into a fully integrated commercial organization.
Cogent Biosciences has announced positive updated lead-in data from its ongoing Phase 3 PEAK trial evaluating bezuclastinib in combination with sunitinib for treating gastrointestinal stromal tumors (GIST). The combination achieved a median progression-free survival (mPFS) of 19.4 months and a 33% objective response rate (ORR) in a subset of patients. The data will be presented at the ASCO Annual Meeting on June 1, 2024.
In addition, Cogent announced a new Phase 2 trial of bezuclastinib plus sunitinib, sponsored by the Sarcoma Alliance for Research through Collaboration (SARC), targeting later-line GIST patients. Enrollment in the PEAK trial is ahead of schedule, now expected to be completed in Q3 2024. The treatment continues to show a favorable safety profile.
Cogent Biosciences, Inc. (Nasdaq: COGT) reported on track clinical trial enrollment for three studies with topline results expected in 2025. The company ended the first quarter of 2024 with $435.7 million in cash, sufficient to fund operations until 2027. Recent business highlights include positive clinical data from SUMMIT trial and oversubscribed private placement.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.